Supercharging a New FDA: Marty Makary on Science, Power & Patients

All-In PodcastJan 15, 20261h 29min

Dr. Marty Makary presents his vision for radically reforming the FDA, arguing that America's regulatory bureaucracy has become a competitive liability in the global race for medical innovation. He makes the case that while China approves Phase 1 trials in four weeks, the U.S. takes over a year for simple nutrition surveys, and proposes using AI and streamlined processes to cut approval times from 60 days to one day.

Key takeaways

•The U.S. FDA takes 18 months to approve simple nutrition surveys while China processes Phase 1 trials in four weeks, creating a massive competitive disadvantage in medical innovation.
•America prescribes significantly more vaccine doses than the international consensus among 20 other developed countries, suggesting potential over-vaccination compared to global standards.
•AI technology could reduce FDA application completeness reviews from 60 days to one day, representing a 6000% efficiency gain in regulatory processing.
•Federal agencies contain absurd inefficiencies like dedicated 'fax machine ink cartridge specialists,' highlighting the need for comprehensive bureaucratic reform.
•The U.S. is currently losing the global medical innovation race to countries with more efficient regulatory frameworks, requiring immediate modernization to remain competitive.

Listen to full episode

0:00

Best moment

10:08· 42sBold/Contrarian

That kind of stuff is intolerable when we're competing with China where they're doing phase ones in four weeks. With Australia, that's doing phase ones in six weeks.

10:08 / 10:50

That kind of stuff is intolerable when we're competing with, China where they're doing phase ones in four weeks. With, Australia, that's doing phase ones in six weeks. And so we need to, have more centralized IRBs and we need to streamline the hospital contracting. Because right now, if you wanna do a trial, each hospital wants to negotiate their margin of what they want and ensure they have to customize the contract because every study is different, has different requirements and resources that are needed. But you go to Australia and they say, sure, sign here on the dotted line. You have access to these 14 hospitals or so. And so, we have got to have more centralized contracting and a centralized

Full clip page →

6 clips

Ordered by timestamp. Jump to the moment you care about.

All-In Podcast

Consequences

There is a race, and when we came to office, we were losing that race. We were behind. We were getting clocked by China, by Australia.

High-stakes competitive framing with vivid language ('getting clocked') that positions US biotech leadership as under threat. Creates urgency around regulatory reform through international competition lens.

8:57 - 9:2831s

All-In Podcast

Business Mechanics

At Johns Hopkins, I had a study, took a year and a half to go through the IRB. It was a survey. What are we worried about? It was a nutrition survey.

Personal anecdote with absurd timeline (1.5 years for a nutrition survey) that illustrates regulatory dysfunction. The rhetorical question 'What are we worried about?' adds incredulity and makes the bureaucratic overreach tangible.

9:49 - 10:2334s

All-In Podcast

Bold/Contrarian

That kind of stuff is intolerable when we're competing with China where they're doing phase ones in four weeks. With Australia, that's doing phase ones in six weeks.

Direct competitive framing with specific timelines (4 weeks vs 6 weeks) that highlight US inefficiency. The word 'intolerable' adds emotional weight while contrasting US bureaucracy with international competitors. Perfect soundbite format.

10:08 - 10:5042s

All-In Podcast

Consequences

Sixty days just for the FDA to tell you that your application is complete. We're gonna get that down to one day. We're gonna use AI.

Dramatic efficiency improvement promise (60 days to 1 day) with AI as the solution. Shows concrete reform vision with measurable outcomes that demonstrates how technology can solve bureaucratic delays.

11:15 - 11:5338s

All-In Podcast

Bold/Contrarian

The guy's job was the ink guy on the fax machine. Just to swap out the ink cartridge. There's a lot of that.

Absurd bureaucratic waste example that's instantly quotable and relatable. The specificity of 'ink guy on the fax machine' creates a memorable image of government inefficiency that audiences can easily share and remember.

33:05 - 33:4439s

All-In Podcast

Business Mechanics

We looked at 20 other developed countries and found that not only are we the international outlier in how high the number of doses we recommend is, but that there's a consensus of a group of core essential vaccines.

Data-driven contrarian take (20 countries, specific dose count of 38) that challenges conventional vaccine policy. Positions US as 'international outlier' which creates controversy while providing concrete framework for reform.

52:40 - 53:2141s

From the blog

FrameworkOriginal Research

The 5 Clip Archetypes for VC Podcasts

10 min read

Want clips like this for your podcast?

We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.

Get 2 Episodes Clipped Free

Supercharging a New FDA: Marty Makary on Science, Power & Patients

Key takeaways

Listen to full episode

Best moment

That kind of stuff is intolerable when we're competing with China where they're doing phase ones in four weeks. With Australia, that's doing phase ones in six weeks.

Transcript

6 clips

There is a race, and when we came to office, we were losing that race. We were behind. We were getting clocked by China, by Australia.

At Johns Hopkins, I had a study, took a year and a half to go through the IRB. It was a survey. What are we worried about? It was a nutrition survey.

That kind of stuff is intolerable when we're competing with China where they're doing phase ones in four weeks. With Australia, that's doing phase ones in six weeks.

Sixty days just for the FDA to tell you that your application is complete. We're gonna get that down to one day. We're gonna use AI.

The guy's job was the ink guy on the fax machine. Just to swap out the ink cartridge. There's a lot of that.

We looked at 20 other developed countries and found that not only are we the international outlier in how high the number of doses we recommend is, but that there's a consensus of a group of core essential vaccines.

From the blog